Therabron

United States
Barbourmeade, Kentucky, United States, 20850

Company profile

Therabron company profile

Therabron Therapeutics, we are working to change how respiratory diseases are managed. We are aiming to not only provide symptomatic relief, but also to improve long-term health outcomes and reduce healthcare costs. A privately held, clinical-stage, biopharmaceutical corporation, Therabron is developing a new class of drugs from the secretoglobin family of proteins. Our lead product, recombinant human CC10 protein (rhCC10), is a potent anti-inflammatory agent for patients with respiratory diseases.

Business identity

Contact email
[email protected]
Phone number
(240) 205-7271
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2007-01-01, Year

Headquarters

Postal code
20850
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$17.9M
Last funding
Debt Financing / 2016-12-12
Last equity funding
Series B / $6.8M
Investors
1
Lead investors
1
Founders
1
Articles
3

Founders and investors

Founders

Aprile Pilon

Lead investors

Brace Pharma

Investors

Brace Pharma